De Burlo Group’s Myriad Genetics MYGN Stock Holding History

De Burlo Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$1.91K	–	148
2022 Q3	$1.91K	Buy	+100	New	+$2.29K	﹤0.01%	180
2022 Q2	–	Sell	-100	Closed	-$2.52K	–	159
2022 Q1	$2.52K	Buy	+100	New	+$2.56K	﹤0.01%	166
2014 Q4	–	Sell	-129,300	Closed	-$4.99M	–	114
2014 Q3	$4.99M	Sell	129,300 -250	-0.2%	-$9.33K	1.1%	35
2014 Q2	$5.04M	Buy	129,550 +24,200	+23%	+$900K	1.14%	37
2014 Q1	$3.6M	Buy	+105,350	New	+$3.26M	0.87%	46

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

De Burlo Group's MYGN Position: Q4 2022 in Review

De Burlo Group sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 100 shares — an estimated $1.91K sold.

De Burlo Group first reported a position in MYGN in Q1 2014 and held it in 5 quarters. The position peaked at $5.04M in Q2 2014. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

De Burlo Group reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
De Burlo Group sold 100 Myriad Genetics shares in Q4 2022, an estimated $1.91K.
De Burlo Group first reported a position in Myriad Genetics in Q1 2014 and held it in 5 quarters.
De Burlo Group's Myriad Genetics position peaked at $5.04M in Q2 2014.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on De Burlo Group's 13F filing for Q4 2022, filed 14 Feb 2023.